PharmaVentures Monthly Podcast Series

Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI.

Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape.

Listen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals.

Listen as Colin McCall, Partner – Life Sciences and Deep Tech at Taylor Wessing, and Oliver Pumfrey, Managing Director at FTI Consulting, talk with Adrian Dawkes about law and tax during the licensing and M&A deal making process.

Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace.

Listen as Andrew Guise gives key insight into the deal making landscape – asset value, accessing the market, positioning and the actual deal process in the current economic climate – from the unique position standing astride both the financial world and the technical world translating science into value.

Listen as Frank Dollard, Steve Garland and Jansen Jacob discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice.

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.

Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.

Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK. A rare opportunity to hear from one of the most experienced regulatory advisors in this important space.

Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine.

Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine.